The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression

Lauren Folgosa Cooley; A. Gordon Robertson; Joshua J. Meeks

doi:10.1007/978-3-030-80546-3_6

The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression

Lauren Folgosa Cooley, A. Gordon Robertson, Joshua J. Meeks^*

^*Corresponding author for this work

Urology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.

Original language	English (US)
Title of host publication	Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
Subtitle of host publication	Multidisciplinary Management
Publisher	Springer International Publishing
Pages	63-73
Number of pages	11
ISBN (Electronic)	9783030805463
ISBN (Print)	9783030805456
DOIs	https://doi.org/10.1007/978-3-030-80546-3_6
State	Published - Jan 1 2022

Keywords

Biomarkers
Bladder cancer
Immune response
Neoadjuvant checkpoint inhibition
Stroma

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-80546-3_6

Cite this

Cooley, L. F., Robertson, A. G., & Meeks, J. J. (2022). The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression. In Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management (pp. 63-73). Springer International Publishing. https://doi.org/10.1007/978-3-030-80546-3_6

@inbook{6576f6744571439ca65057af83a0eb64,

title = "The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression",

abstract = "Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.",

keywords = "Biomarkers, Bladder cancer, Immune response, Neoadjuvant checkpoint inhibition, Stroma",

author = "Cooley, {Lauren Folgosa} and Robertson, {A. Gordon} and Meeks, {Joshua J.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-030-80546-3_6",

language = "English (US)",

isbn = "9783030805456",

pages = "63--73",

booktitle = "Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers",

publisher = "Springer International Publishing",

}

Cooley, LF, Robertson, AG & Meeks, JJ 2022, The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression. in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management. Springer International Publishing, pp. 63-73. https://doi.org/10.1007/978-3-030-80546-3_6

The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression. / Cooley, Lauren Folgosa; Robertson, A. Gordon; Meeks, Joshua J.
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management. Springer International Publishing, 2022. p. 63-73.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition

T2 - Contextualizing the Treatment-Induced Changes in Gene Expression

AU - Cooley, Lauren Folgosa

AU - Robertson, A. Gordon

AU - Meeks, Joshua J.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.

AB - Although neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC), immune checkpoint inhibitors have shown promising results in this setting. Phase II and III data of neoadjuvant programmed cell death-1 (PD-1) receptor/PD-1 ligand (PD-L1) inhibitors are now available with biomarker analyses of pre- and posttreatment tumors to help guide precision-based treatment to individual tumors. While still in its infancy, this review of available neoadjuvant immunotherapy trials (PURE-01, ABACUS, NABUCCO) and their biomarker analyses can contextualize the molecular and immunology-based biomarkers to improve prediction of individual patient response and outcomes.

KW - Biomarkers

KW - Bladder cancer

KW - Immune response

KW - Neoadjuvant checkpoint inhibition

KW - Stroma

UR - http://www.scopus.com/inward/record.url?scp=85153819336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85153819336&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-80546-3_6

DO - 10.1007/978-3-030-80546-3_6

M3 - Chapter

AN - SCOPUS:85153819336

SN - 9783030805456

SP - 63

EP - 73

BT - Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers

PB - Springer International Publishing

ER -

The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this